Eli Lilly Introduces Affordable Zepbound Vials to Address Obesity Drug Shortage

The new program offers single-dose vials at half the price to increase accessibility and supply of the weight-loss medication.

Zepbound vials will be available for $399 per month, significantly lower than other obesity drugs.
The initiative aims to ease the ongoing shortage of Zepbound in the U.S.
Patients must have a valid prescription and purchase through the LillyDirect program.
Experts commend the move as a step towards more equitable access to weight-loss treatments.
The program excludes delivery pens and syringes, focusing on affordability and availability.